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Background: Two-thirds of all patients with arterial hypertension need drug combinations 
to achieve blood pressure (BP) goals. Fixed combinations have high efficacy and result in 
high patient compliance. 300 mg irbesartan plus 25 mg hydrochlorothiazide (HCTZ) has been 
investigated only in clinical trials but not in daily practice.
Methods: A multicenter, noninterventional, noncontrolled observational study with 8123 patients 
seen by 1604 physicians in daily practice. BP reduction (office measurements), co-morbid disease 
and tolerability were documented over a 6-month observational period.
Results: At mean baseline BP of 161 ± 15/94 ± 10 mmHg, administering of fixed combination 
resulted in a substantial BP reduction averaging 28 ± 15/14 ± 10 mmHg (P  0.001). Decrease 
of systolic BP ran parallel with increasing systolic baseline BP (Spearman’s Rho –0.731; 
P  0.0001; diastolic BP vs diastolic baseline BP Rho 0.740; P  0.0001), independent from 
patient characteristics (age, obesity, diabetes or nephropathy) but enhanced with short history of 
hypertension (P  0.0001 vs long history), prior beta blockers (P = 0.001 vs prior angiotensin 
receptor blockers [ARBs]), prior calcium channel blockers (P = 0.046 vs prior ARBs) and no 
prior medication (P = 0.012 vs prior ARBs). High compliance (98%) and low incidence of 
adverse events (0.66%) were documented.
Conclusions: The fixed combination of 300 mg irbesartan with 25 mg HCTZ was efficacious 
and tolerable in an unselected patient population in primary care.
Keywords: hypertension, combination therapy, obesity, irbesartan, noninterventional study, 
diuretics
Introduction
Arterial hypertension is one of the commonest direct or indirect causes of increased 
cardiovascular morbidity and mortality worldwide. Its prevalence, for example, in the UK 
is 42%, in Spain it is 47% and in Germany it is 55%, while the rate in the US and in Canada 
is 28% and 27% respectively.1 Despite this strikingly high prevalence, the control rate 
of treated patients worldwide is low. Even in the US, only half of all treated patients 
achieve the target values (53.1%), and in Germany the figure is only 33.6%.2 An average 
reduction in systolic blood pressure of 2 mmHg would in fact be associated with a 7% 
reduction in the stroke rate and a 10% reduction in ischemic heart diseases.3
Since many patients are not adequately controlled with monotherapy, nowadays the 
majority of patients are treated with a combination of 2 or more antihypertensive drugs. Vascular Health and Risk Management 2009:5 992
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In Germany around one-third of patients receive monotherapy, 
one-third a combination of 2 substances and one-third a com-
bination of 3 and more drugs (IMS Datamonitor 2003). The 
relevant guidelines4,5 recommend that combination therapy 
should be initiated early. The guidelines of the ESH/ESC 
20075 provide for the use of combination therapy if mono-
therapy is unsuccessful after the antihypertensive agent 
has been changed and in high dosages, or if patients with 
high cardiovascular risk present with blood pressure values 
which are 20/10 mmHg above the target values. Nowadays 
the general recommendation for combination therapy is the 
combination of blockers of the renin-angiotensin system with 
thiazide diuretics or calcium antagonists.4,5 The advantage 
of a fixed dose combination is increased compliance, which 
ensures effective and lasting control of blood pressure.
Irbesartan has proved effective in reducing blood pressure 
in a number of clinical studies.6–8 With the fixed combina-
tion of 300 mg irbesartan and 25 mg hydrochlorothiazide 
(HCTZ), a high-dose combination has been available for 
some time now which achieves an even greater reduction in 
blood pressure.9 In addition, the RAPiHD study showed that 
the primary use of this combination in patients with severe 
hypertension is also effective and well tolerated.10
However, the results from randomized, controlled stud-
ies cannot be applied without further evaluation in everyday 
practice, because of their specific patient selection, close 
monitoring and generally short duration. The aim of the 
noninterventional study on hand was therefore to investigate 
the efficacy of the high-dose combination therapy under 
practice conditions in a non-selected patient population, and 
to document possible rare, so far undetected side effects of 
this fixed combination.
Patients and methods
The noninterventional, noncontrolled study was conducted 
with the aid of practice-based doctors throughout Germany 
(i-Control). These were a random sample of specialists in 
general medicine, internal medicine, cardiology and of practi-
tioners from all the regions defined by the Institute of Medical 
Statistics (IMS). The study was registered in accordance with 
§ 67 (6) German Drugs Law (AMG) at the Federal Institute of 
Drugs and Medical Devices (BfArM) and at the National Asso-
ciation of Statutory Health Insurance Physicians (KBV).
issue investigated
The investigation was conducted in order to document 
the efficacy and tolerability of the fixed combination of 
irbesartan 300 mg/HCTZ 25 mg (CoaprovelTM 300 mg/25 mg; 
sanofi-aventis Deutschland GmbH, Berlin) in patients 
with arterial hypertension who had previously received 
pharmacotherapy and whose blood pressure was so far 
not controlled by other antihypertensives.
Patients
Patients were documented who at the time of the investigation 
were at least 18 years old, showed primary arterial hyper-
tension with blood pressure values 140/90 mmHg 
(diabetics 130/80 mmHg) and in whom previous 
pharmacotherapy of the hypertension had not resulted in 
the target blood pressure being achieved. In addition, the 
doctors had a free selection of patients within the scope of 
drug licensing (indications and contraindications), that is, 
no other inclusion and exclusion criteria were defined. They 
were also able to adjust the dosage of the concomitant medi-
cation throughout the duration of the study as desired.
Documented variables
At the enrolment visit, demographic data (age and gender) 
and also anamnestic data relating to cardiovascular risk fac-
tors were collected. In addition the weight, height, abdominal 
measurement (waist circumference), hip measurement, dis-
eases related to the hypertension, previous antihypertensive 
therapy and concomitant medication, as well as a number of 
laboratory values for classification into certain risk groups 
were documented. At the optional check-up after 3 months, 
changes in blood pressure and medication as well as the 
occurrence of adverse events were documented. At the end 
of the observation after 6 months, a number of demographic 
data were again measured in the practice and blood pressure 
readings, medication and changes in the laboratory values 
were documented. In particular, the individual target blood 
pressure value for the documented patient was requested at 
the start of the investigation and it was verified that it had been 
achieved during the further course of the investigation.
execution
The physicians were asked to document patients who were 
being treated with a combination of irbesartan 300 mg/HCTZ 
25 mg because of inadequately controlled primary arterial 
hypertension. The documentation forms were recorded by the 
Clinical Research Organization (CRO) factum – Gesellschaft 
für Statistik, wissenschaftliche Information und Kommunika-
tion mbH, Offenbach. The data in all documentation forms 
were examined for their plausibility. The documentation 
forms did not undergo comparison with the source documents 
for monitoring. The patients were recorded in pseudonymized Vascular Health and Risk Management 2009:5 993
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form, ie, only the age and gender of the patient were entered 
in the documentation, and all data collected during the 
observation were treated confidentially. Data were electroni-
cally stored in accordance with data protection provisions. 
The fees for documentation activities were paid in accordance 
with the official scale of physicians’ fees (Gebührenordnung 
für Ärzte, GOÄ).
Adverse drug reactions
Adverse drug reactions (ADRs) were explicitly asked about 
and recorded in detail (nature, date, duration, result, and 
causal relationship with the therapy). All physicians were 
asked to report serious adverse events to the pharmaceuti-
cal manufacturer immediately, which notified the BfArM in 
accordance with legal requirements.
Statistics
The statistical analysis was descriptively conducted, explor-
atively assessed, and then produced in tabular and graphic 
form. For categorical data absolute and relative frequencies 
and for steady variables average and standard deviation 
were calculated. The confidence intervals were calculated 
with the aid of the statistics program BIAS Version 8.4.6, 
publ. epsilon for theta of a binomial distribution; all other 
calculations were performed with the aid of the statistics 
program SPSS for Windows (Release 15.0). The statistical 
testing procedures conducted were the Mann–Whitney U test 
or the Kruskal–Wallis test for group differences in terms of 
changes in blood pressure. The Spearman’s Rho was used 
for rank correlations (relationship of initial blood pressure 
to reduction in blood pressure). In order to be able to record 
rare ADRs, the number of cases was set at 8000 patients: this 
allows ADRs up to an incidence of 0.1% to be recorded with 
a probability of almost 100% and ADRs with an incidence 
of 0.01% with a probability of 55.1%.
Results
A total of 8123 patients were included in the observation 
between November 2006 and January 2008 in 1604 centers 
(median: 5 patients per center).
The patients had an average age of 63.4 ± 11.3 years. 
50.8% of them were male, and the patients had an average 
BMI of 29.4 ± 4.9 kg/m2. The initial blood pressure was 
160.5 ± 15.3/93.9 ± 9.6 mmHg with an average duration of 
hypertension of 8.4 years (Table 1). No concomitant diseases 
were present in 14.1% of the patients. The most common 
concomitant diseases were lipid metabolic disorders (53.7%), 
diabetes mellitus (38.8%) and metabolic syndrome (19.1%).
Medication
During the observation phase all patients received 300 mg 
irbesartan/25 mg HCT. In addition, some patients received 
further concomitant medication, comprising after 6 months 
37.2% beta blockers, 25.3% calcium antagonists, 12.8% 
diuretics and 8.4% angiotensin-converting enzyme (ACE) 
inhibitors. Concomitant medication with alpha blockers or 
aldosterone antagonists was rare (Table 2). When making the 
decision in favor of a combination, the doctors most com-
monly switched from an ACE inhibitor medication (54.7%), 
diuretics (50.3%) and beta blockers (49.0%).
Antihypertensive effect according 
to baseline blood pressure
After a follow-up observation of 6 months the systolic blood 
pressure was reduced on average by 27.9 ± 15.2 mmHg and 
the diastolic by 14.0 ± 10.2 mmHg compared with the initial 
blood pressure (in each case P  0.001 compared with initial 
value). Based on a target value of 140/90 mmHg, 68.6% of 
the patients were normalized (systolic normalization 71.9%, 
diastolic 88.3%).
Figure 1A presents the reduction in systolic blood pres-
sure achieved as a function of the initial systolic blood 
Table 1 Patient characteristics at the start of therapy
Patient population Evaluable  
data (n)
Values
Total number of patients 8123
Men (%) 8037 50.8
Age (years; mean ± SD) 7970 63.4 ± 11.3
Body weight (kg; mean ± SD) 8083 85.8 ± 16.0
BMi (kg/m2; mean ± SD) 8079 29.4 ± 4.9
Smokers (%) 7589 22.8
Blood pressure practice measurement
  Systolic (mmHg; mean ± SD) 8096 160.5 ± 15.3
  Diastolic (mmHg; mean ± SD) 8094 93.9 ± 9.6
Duration of hypertension  
(years; average ± SD)
7952 8.4 ± 6.5
Concomitant diseasesa
Diabetes mellitus (%) 8102 38.8
Peripheral arterial disease (%) 8102 6.3
Diabetic nephropathy (%) 8102 4.8
s/p myocardial infarction (%) 8102 6.9
Lipid metabolic disorder (%) 8102 53.7
Cardiac insufficiency (%) 8102 8.2
s/p stroke (%) 8102 4.4
no concomitant diseases (%) 8102 14.1
aPhysician defined, no specific testing.
Abbreviations: SD, standard deviation; BMi, body mass index; s/p, status post.Vascular Health and Risk Management 2009:5 994
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pressure (Rho –0.731; P  0.0001). Figure 1B presents the 
reduction in diastolic blood pressure achieved as a function of 
the diastolic initial blood pressure (Rho -0.740; P  0.0001). 
Figures 2A and B shows the proportion of patients with nor-
malized blood pressure as a function of the systolic/diastolic 
initial blood pressure. Here, too, a direct dependence of 
the frequency of normalization on the systolic initial blood 
pressure is shown: the higher the initial blood pressure, the 
lower was the normalization of both parameters of systolic 
and diastolic blood pressure.
Antihypertensive efficacy according  
to patient characteristics
Depending upon classification of the patient population 
based on the parameters of age, BMI, diabetes, duration 
of hypertension, nephropathy and previous therapy, the 
values for the reduction in systolic blood pressure ranged 
from –26.8 to –30.2 mmHg. The reduction in blood pressure 
did not depend on patient characteristics such as age, obesity, 
diabetes and nephropathy. In contrast, the reduction in blood 
pressure in the case of short duration of the disease was 
increased vs long duration (P  0.0001). Likewise blood 
pressure reduction in case of prior treatment with beta block-
ers (P = 0.001), calcium antagonists (P = 0.046) and no prior 
therapy (P = 0.012) was increased compared with angiotensin 
receptor blockers (Figure 3).
compliance
Most (96.5%) of the patients took the medication for the 
whole duration of the observational period (2.1% not speci-
fied). Of the 110 patients (1.36%) who terminated the therapy 
prematurely (22 because of adverse events), 44.6% were male 
and 17.3% were smokers. The average age of drop-outs was 
64.7 ± 12.5 years, and the average BMI was 29.8 ± 4.8 kg/m2. 
Of the drop-outs, 88.2% had concomitant diseases, with 
lipid metabolic disorders at 47.3% and diabetes mellitus 
and obesity (BMI  30 kg/m²) each at 41.82% being most 
commonly represented.
Tolerability of the therapy
Adverse events occurred during the observation in a total of 
54 patients (0.66%). These were classified as ADRs in 35 
patients (0.43%) (Table 3). The adverse event was rated as 
serious in a total of 12 patients (5 with ADRs).
ADRs are listed in Table 4. The serious ADRs 
included: transient ischemic attacks with signs of paraly-
sis, ischemic optic neuropathy with visual impairment or 
blindness in the left eye, death of a patient as a result of 
carcinoma (the doctors considered a connection with the 
medication to be unlikely for the patients named above), 
myocardial infarction (unrelated or unlikely related), 
and also hypotension and vertigo (doctors’ opinion: 
possible).
Table 2 Therapy of arterial hypertension before and during observation
Before  
the study
After start  
of study
After  
3 months
After  
6 months
n % n % n % n %
Ace inhibitors 4435 54.7 664 8.2 649 8.0 682 8.4
Beta blockers 3976 49.0 2946 36.3 2945 36.3 3015 37.2
Diuretics 4081 50.3 1068 13.2 996 12.3 1042 12.8
calcium antagonists 2569 31.7 1878 23.2 1931 23.8 2052 25.3
AT1 blockers 2159 26.6 –a –a –a –a –a –*
Alpha blockers 378 4.7 292 3.6 285 3.5 308 3.8
Aldosterone antagonists 144 1.8 114 1.4 112 1.4 127 1.6
irbesartan 300 mg/HcTZ 25 mg –a –a 8110 100.0 7855 96.9 7869 97.0
Other 651 8.0 544 6.71 536 6.6 597 7.4
no medication 104 1.3 0 0.0 0 0.0 9 0.1
1 active substance group 1779 21.9 0 0.0 25 0.3 51 0,6
2 active substance group 2745 33.8 3812 47.0 3642 44.9 3634 44.8
3 active substance group 2082 25.7 2679 33.0 2611 32.2 2,622 32.3
3 active substance groups 1310 16.2 1619 20.0 1629 20.1 1697 20.9
Not specified 90 1.1 0 0.0 203 2.5 97 1.2
airbesartan/HcTZ was not asked about at the start and other AT1 blockers were not asked about during the course of the study.
Abbreviations: ACE, angiotensin-converting enzyme; HCTZ, hydrochlorothiazide.Vascular Health and Risk Management 2009:5 995
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Discussion
The patients documented in this noninterventional 
observational study were predominantly hypertensive 
patients with increased cardiovascular risk, whose blood 
pressure was so far not controlled, or only inadequately 
controlled, by monotherapy or low-dose combination 
therapy. Current guidelines recommend initial high-dose 
combination therapy for such patients.4,5 Observation of 
the use of irbesartan 300 mg/HCTZ 25 mg over a period of 
6 months produced the following important findings in this 
context: 1) The use of the fixed combination resulted in a 
clear further reduction in blood pressure (27.9/14.0 mmHg, 
P  0.001). 2) An almost linear increase in efficacy can be 
expected depending on the systolic initial blood pressure. 
The higher the initial blood pressure, the greater the 
decrease in blood pressure. This might be significant 
especially for older patients with predominantly increased 
systolic blood pressure. 3) The efficacy is quantitatively 
not dependent on the presence of a range of concomitant 
diseases. 4) High compliance of 98% because of a low 
incidence of adverse events (0.66%) facilitates long-term 
adequate control of blood pressure.
Efficacy of irbesartan 300 mg/HCTZ 
25 mg in everyday practice
In 1999 Kochar et al9 tested the antihypertensive efficacy 
of the combination of irbesartan and HCTZ in various dos-
ages for 8 weeks in a matrix study. At an average initial 
Figure 1 Reduction in blood pressure (BP) after 6 months as a function of the systolic A) and diastolic B) initial blood pressure value.
Mean blood pressure reduction overall:
Systolic BP: –27.9 mmHg (P ≤ 0.001)
Correlation systolic blood pressure at baseline vs blood pressure reduction
Spearman’s rho systolic BP: –0.731 (P < 0.001 vs baseline)
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blood pressure of 151 ± 14.7/100 ± 4.2 mmHg, an average 
reduction in blood pressure of 23.1 ± 15.0/14.4 ± 8.0 was 
achieved in this study with irbesartan 300 mg/HCTZ 25 mg. 
In a further study of Neutel, patients with severe hyperten-
sion (initial blood pressure 171.5/77.4 mmHg) were treated 
for 7 weeks with the irbesartan/HCTZ high-dose combina-
tion.10 A reduction in blood pressure of 31.7/24.5 mmHg 
was achieved. The results of the noninterventional study 
supplement these data and findings with data from everyday 
clinical practice. The reduction in systolic blood pressure 
extrapolated from the clinical studies for this initial blood 
pressure is 27.4; in fact an average reduction in blood pres-
sure of 27.9 mmHg was achieved. Because of the lack of 
a wash-out phase, the lack of guidance for the changeover 
and the lack of concomitant medication, in theory a lower 
reduction in blood pressure would be expected, but this was 
not confirmed in the study.
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Figure 3 Reduction in systolic blood pressure (BP) (mmHg) as a function of defined patient characteristics/previous medication. Use of the Kruskal–Wallis Test for differences 
within groups. Significant P-values for pairwise comparisons are indicated;     other comparisons are not significant.    Age: Lower tercile (LT) up to 58 years, middle tercile (MT)  
58 to 69 years, upper tercile (UT)  69 years; body mass index (BMi): LT up to 25 kg/m², MT  25 to 30 kg/m², UT  30 kg/m²; duration of hypertension: LT up to 5 years, 
MT  5 to 10 years, UT  10 years.
Abbreviations: Ace, angiotensin-converting enzyme; CCBs, calcium channel blockers.
Table 3 Number of patients with adverse events (AE) without 
causal relationship or adverse drug reactions (ADR) in the 
observation period
Total population (n = 8123) 
(multiple answers possible)
n %
Patients without Ae 8,056 99.18
Patients with Ae 54 0.66
  Serious 12 0.15
  not serious 43 0.53
Therapy discontinued 22 0.27
because of AE
Patients with ADR 35 0.43
  Serious 5 0.06
  not serious 30 0.37
No verification possible 13 0.16
Notes: Binominal confidence interval calculated according to BIAS Version 8.4.6.Vascular Health and Risk Management 2009:5 998
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of high-dose fixed combinations in everyday practice are 
not yet available.
Predictor of reduction in blood pressure
The antihypertensive efficacy of substances is quite decisively 
dependent on the blood pressure values at the start of the 
study.15 A range of studies has shown that the higher the initial 
value, the higher the achievable reduction in blood pres-
sure16,17 or the more common is the normalization of blood 
pressure after the start of therapy16–19 (see also Figure 4). This 
might be related to a regression to the mean phenomenon in 
single patients but certainly not in the majority of patients 
in this study of more than 8123 patients. Thus the average 
reduction in blood pressure in the study of Schühlen et al was 
26.8/13.5 mmHg, and in patients with severe hypertension 
To date there are no direct comparisons available of the 
relative efficacy of irbesartan 300 mg/HCTZ 25 mg with 
fixed combinations of other sartans with 25 mg HCTZ. 
However the relative efficacy from the comparison of 
substances in monotherapy7,8,11 is generally maintained for 
the corresponding combinations with HCTZ.12,13 These 
studies showed a greater reduction in blood pressure from 
150 mg irbesartan compared with 50 mg losartan7,11,13 
both with and without HCTZ. In a study with losartan 
100 mg/HCTZ 25 mg, a reduction in blood pressure of 
24.0/11.8 mmHg was achieved at an initial blood pressure 
of 160.8/94.4 mmHg.14 These data are largely comparable 
with the data on hand (reduction in blood pressure 27.9/14.0 
at an initial blood pressure of 160.5/93.9 mmHg), even if 
they are nominally higher. Other data relating to the efficacy 
Figure 4 Systolic normalization (140 mmHg) according to systolic initial blood pressure value in the studies RAPiHD severe10 and RAPiHD moderate24 (after Franklin)18. 
RAPiHD severe was a 7-week trial in patients with severe hypertension (seated DBP [SeDBP]  110 mmHg). Eligible patients entered a 7-day single-blind placebo lead-in period. 
Patients with SeDBP  110 mmHg at 2 consecutive visits during the lead-in period were randomized in a 2:1 ratio to irbesartan/HCTZ 150/12.5 mg fixed-dose combination 
therapy force-titrated to 300/25 mg after week 1 or irbesartan 150 mg monotherapy force-titrated to 300 mg after week 1. RAPiHD moderate was a 12-week trial in patients 
with moderate hypertension (seated SBP [SeSBP] 160–180 mmHg or SeDBP 100–110 mmHg). Eligible patients entered a 21-day single-blind placebo wash-out period before 
randomization in a 3:1:1 ratio to irbesartan/HCTZ 150/12.5 mg fixed-dose combination therapy force-titrated to 300/25 mg after week 2, irbesartan 150 mg monotherapy 
force-titrated to 300 mg after week 2, or HCTZ 12.5 mg monotherapy force-titrated to 25 mg after week 2.
Abbreviation: HcTZ, hydrochlorothiazide.
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Table 4 Adverse drug reactions (ADR) coded according to 
MedDRA®   Version 10.0
Total population (n = 8123) 
MedDRA® primary System  
Organ Classes (SOC)
n %
Patients with ADR 35 0.43
  cardiac disorders 2 0.02
  eye disorders 1 0.01
  gastrointestinal disorders 5 0.06
  general disorders and administration site conditions 5 0.06
  investigations 1 0.01
  Metabolism and nutrition disorders 2 0.02
  Musculoskeletal and connective tissue disorders 1 0.01
  nervous system disorders 15 0.18
  Renal and urinary disorders 1 0.01
  Respiratory, thoracic and mediastinal disorders 4 0.05
  Skin and subcutaneous tissue disorders 4 0.05
  Vascular disorders 6 0.07
Patients without ADR 8075 99.41
Verification not possible 13 0.16
Total 8123 100.0
(41.7/20.5 mmHg). In particular, an analysis of the predic-
tion of the reduction in blood pressure in the INCLUSIVE 
study showed that an increase of 1 mmHg in the systolic 
initial blood pressure can predict an additional reduction of 
0.9 ± 0.1 mmHg in the systolic blood pressure.20 The study 
presented here also shows a linear relationship between the 
systolic/diastolic blood pressure at the start of the study and 
the achievable reduction in blood pressure (Figure 1). On 
the other hand, the incidence of hypotension in the study on 
hand is rare, even in higher dosages. Clear effects on blood 
pressure are not expected in normotensive patients. Out of 
over 8123 patients, only 13 terminated the therapy because 
of vertigo or hypotension.
The analysis of the study on hand continued to show 
no dependency of the reduction in blood pressure on age, 
diabetes, weight and nephropathy. These results therefore 
confirm previous analyses of the efficacy of irbesartan/HCTZ 
in various patient populations.10,21–23 In contrast, the predic-
tor analysis of the INCLUSIVE study reported that higher 
reductions in blood pressure were to be expected in patients 
with higher initial blood pressure values (see above), type 2 
diabetes (+5.0 mmHg), with statin intake (+2.1 mmHg) and 
for women (+3 mmHg).20
compliance and tolerability
Irbesartan is well tolerated both in monotherapy and also in 
combination with HCTZ. In a pooled analysis18 of the two 
RAPiHD studies (moderate and severe),10,24 37.0% adverse 
events occurred, which were ascribed to the medication in 
12.5% of the patients (0.9% serious). These figures were 
only slightly raised compared with irbesartan monotherapy. 
In the healthcare study on hand, 1% adverse events were 
reported; 0.43% were linked to the medication (0.06% 
serious).
Conclusions
The fixed combination of 300 mg irbesartan and 25 mg HCTZ 
is effective and well tolerated. The effect increases depending 
on the initial blood pressure, but is largely independent of 
various patient characteristics. This study thus confirms the 
data from previous clinical studies for a nonselected patient 
group in everyday practice.
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